Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2

Jun Wang, Chunlong Ma, Giacomo Fiorin, Vincenzo Carnevale, Tuo Wang, Fanghao Hu, Robert A. Lamb, Lawrence H. Pinto, Mei Hong, Michael L. Klein, William F. Degrado

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Influenza A virus M2 (A/M2) forms a homotetrameric proton selective channel in the viral membrane. It has been the drug target of antiviral drugs such as amantadine and rimantadine. However, most of the current virulent influenza A viruses carry drug-resistant mutations alongside the drug binding site, such as S31N, V27A, and L26F, etc., each of which might be dominant in a given flu season. Among these mutations, the V27A mutation was prevalent among transmissible viruses under drug selection pressure. Until now, V27A has not been successfully targeted by small molecule inhibitors, despite years of extensive medicinal chemistry research efforts and high throughput screening. Guided by molecular dynamics (MD) simulation of drug binding and the influence of drug binding on the dynamics of A/M2 from earlier experimental studies, we designed a series of potent spirane amine inhibitors targeting not only WT, but also both A/M2-27A and L26F mutants with IC 50s similar to that seen for amantadine's inhibition of the WT channel. The potencies of these inhibitors were further demonstrated in experimental binding and plaque reduction assays. These results demonstrate the power of MD simulations to probe the mechanism of drug binding as well as the ability to guide design of inhibitors of targets that had previously appeared to be undruggable.

Original languageEnglish (US)
Pages (from-to)12834-12841
Number of pages8
JournalJournal of the American Chemical Society
Volume133
Issue number32
DOIs
StatePublished - Aug 17 2011
Externally publishedYes

Fingerprint

Influenza A virus
Molecular Dynamics Simulation
Drug Delivery Systems
Viruses
Molecular dynamics
Computer simulation
Pharmaceutical Preparations
Amantadine
Mutation
Rimantadine
Binding sites
Amines
Assays
Pharmaceutical Chemistry
Screening
Protons
Throughput
Membranes
Antiviral Agents
Molecules

ASJC Scopus subject areas

  • Chemistry(all)
  • Catalysis
  • Biochemistry
  • Colloid and Surface Chemistry

Cite this

Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. / Wang, Jun; Ma, Chunlong; Fiorin, Giacomo; Carnevale, Vincenzo; Wang, Tuo; Hu, Fanghao; Lamb, Robert A.; Pinto, Lawrence H.; Hong, Mei; Klein, Michael L.; Degrado, William F.

In: Journal of the American Chemical Society, Vol. 133, No. 32, 17.08.2011, p. 12834-12841.

Research output: Contribution to journalArticle

Wang, J, Ma, C, Fiorin, G, Carnevale, V, Wang, T, Hu, F, Lamb, RA, Pinto, LH, Hong, M, Klein, ML & Degrado, WF 2011, 'Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2', Journal of the American Chemical Society, vol. 133, no. 32, pp. 12834-12841. https://doi.org/10.1021/ja204969m
Wang, Jun ; Ma, Chunlong ; Fiorin, Giacomo ; Carnevale, Vincenzo ; Wang, Tuo ; Hu, Fanghao ; Lamb, Robert A. ; Pinto, Lawrence H. ; Hong, Mei ; Klein, Michael L. ; Degrado, William F. / Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. In: Journal of the American Chemical Society. 2011 ; Vol. 133, No. 32. pp. 12834-12841.
@article{87ef2aec8cee43f7ad4fd6dbcc04f3c1,
title = "Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2",
abstract = "Influenza A virus M2 (A/M2) forms a homotetrameric proton selective channel in the viral membrane. It has been the drug target of antiviral drugs such as amantadine and rimantadine. However, most of the current virulent influenza A viruses carry drug-resistant mutations alongside the drug binding site, such as S31N, V27A, and L26F, etc., each of which might be dominant in a given flu season. Among these mutations, the V27A mutation was prevalent among transmissible viruses under drug selection pressure. Until now, V27A has not been successfully targeted by small molecule inhibitors, despite years of extensive medicinal chemistry research efforts and high throughput screening. Guided by molecular dynamics (MD) simulation of drug binding and the influence of drug binding on the dynamics of A/M2 from earlier experimental studies, we designed a series of potent spirane amine inhibitors targeting not only WT, but also both A/M2-27A and L26F mutants with IC 50s similar to that seen for amantadine's inhibition of the WT channel. The potencies of these inhibitors were further demonstrated in experimental binding and plaque reduction assays. These results demonstrate the power of MD simulations to probe the mechanism of drug binding as well as the ability to guide design of inhibitors of targets that had previously appeared to be undruggable.",
author = "Jun Wang and Chunlong Ma and Giacomo Fiorin and Vincenzo Carnevale and Tuo Wang and Fanghao Hu and Lamb, {Robert A.} and Pinto, {Lawrence H.} and Mei Hong and Klein, {Michael L.} and Degrado, {William F.}",
year = "2011",
month = "8",
day = "17",
doi = "10.1021/ja204969m",
language = "English (US)",
volume = "133",
pages = "12834--12841",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "32",

}

TY - JOUR

T1 - Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2

AU - Wang, Jun

AU - Ma, Chunlong

AU - Fiorin, Giacomo

AU - Carnevale, Vincenzo

AU - Wang, Tuo

AU - Hu, Fanghao

AU - Lamb, Robert A.

AU - Pinto, Lawrence H.

AU - Hong, Mei

AU - Klein, Michael L.

AU - Degrado, William F.

PY - 2011/8/17

Y1 - 2011/8/17

N2 - Influenza A virus M2 (A/M2) forms a homotetrameric proton selective channel in the viral membrane. It has been the drug target of antiviral drugs such as amantadine and rimantadine. However, most of the current virulent influenza A viruses carry drug-resistant mutations alongside the drug binding site, such as S31N, V27A, and L26F, etc., each of which might be dominant in a given flu season. Among these mutations, the V27A mutation was prevalent among transmissible viruses under drug selection pressure. Until now, V27A has not been successfully targeted by small molecule inhibitors, despite years of extensive medicinal chemistry research efforts and high throughput screening. Guided by molecular dynamics (MD) simulation of drug binding and the influence of drug binding on the dynamics of A/M2 from earlier experimental studies, we designed a series of potent spirane amine inhibitors targeting not only WT, but also both A/M2-27A and L26F mutants with IC 50s similar to that seen for amantadine's inhibition of the WT channel. The potencies of these inhibitors were further demonstrated in experimental binding and plaque reduction assays. These results demonstrate the power of MD simulations to probe the mechanism of drug binding as well as the ability to guide design of inhibitors of targets that had previously appeared to be undruggable.

AB - Influenza A virus M2 (A/M2) forms a homotetrameric proton selective channel in the viral membrane. It has been the drug target of antiviral drugs such as amantadine and rimantadine. However, most of the current virulent influenza A viruses carry drug-resistant mutations alongside the drug binding site, such as S31N, V27A, and L26F, etc., each of which might be dominant in a given flu season. Among these mutations, the V27A mutation was prevalent among transmissible viruses under drug selection pressure. Until now, V27A has not been successfully targeted by small molecule inhibitors, despite years of extensive medicinal chemistry research efforts and high throughput screening. Guided by molecular dynamics (MD) simulation of drug binding and the influence of drug binding on the dynamics of A/M2 from earlier experimental studies, we designed a series of potent spirane amine inhibitors targeting not only WT, but also both A/M2-27A and L26F mutants with IC 50s similar to that seen for amantadine's inhibition of the WT channel. The potencies of these inhibitors were further demonstrated in experimental binding and plaque reduction assays. These results demonstrate the power of MD simulations to probe the mechanism of drug binding as well as the ability to guide design of inhibitors of targets that had previously appeared to be undruggable.

UR - http://www.scopus.com/inward/record.url?scp=80051595050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051595050&partnerID=8YFLogxK

U2 - 10.1021/ja204969m

DO - 10.1021/ja204969m

M3 - Article

C2 - 21744829

AN - SCOPUS:80051595050

VL - 133

SP - 12834

EP - 12841

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 32

ER -